Effectiveness of a triclosan/copolymer dentifrice on microbiological and inflammatory parameters.
According to the US Surgeon General's report, "Oral Health in America," published in 2000, most adults in the United States show some degree of periodontal pathology, with severe periodontal diseases affecting about 14% of middle-aged adults. Periodontal diseases are polymicrobial-induced inflammatory diseases, and they vary from mild gingival inflammation to severe deterioration of the periodontium, ie, loss of periodontal supportive tissues and, ultimately, tooth loss. New evidence shows that periodontal diseases may impact systemic health. For this reason, the maintenance of a healthy mouth is becoming increasingly important for the overall health of the body. This article summarizes laboratory research conducted during the development of a novel, multibenefit, oral-care technology based on triclosan--a broad-spectrum antibacterial agent--and a polyvinylmethylether/maleic acid copolymer. This unique combination of agents is found in Colgate Total, a clinically proven efficacious dentifrice for control of dental plaque and gingivitis. Data are presented that demonstrate the unique antibacterial properties of this dentifrice: (1) a broad-spectrum antimicrobial profile; (2) the long-lasting retention of triclosan on hydroxyapatite and epithelial cells; and (3) molecular evidence of antibacterial activity against specific pathogens in clinical dental plaque. In addition, data are presented that demonstrate the anti-inflammatory effects of triclosan on specific cytokines, the interruption of inflammatory pathways, and the inhibition of bone resorption. Overall, these data support the multibenefit clinical effects of Colgate Total and suggest a plurality of mechanisms of action.
Xu
Tao
T
The Colgate-Palmolive Company, Technology Center, Piscataway, New Jersey, USA.
Deshmukh
Meenal
M
Barnes
Virginia Monsul
VM
Trivedi
Harsh M
HM
Cummins
Diane
D
D000190:Actinomyces / Q000187:drug effects; D000328:Adult; D016976:Aggregatibacter actinomycetemcomitans / Q000187:drug effects; D000818:Animals; D000891:Anti-Infective Agents, Local / Q000494:pharmacology / Q000627:therapeutic use*; D001439:Bacteroides / Q000187:drug effects; D045424:Complex Mixtures; D003773:Dental Plaque / Q000382:microbiology / Q000517:prevention & control*; D003802:Dentifrices / Q000494:pharmacology / Q000627:therapeutic use*; D005459:Fluorides; D016967:Fusobacterium nucleatum / Q000187:drug effects; D005891:Gingivitis / Q000517:prevention & control*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors*; D007780:Lacticaseibacillus casei / Q000187:drug effects; D016966:Porphyromonas gingivalis / Q000187:drug effects; D012824:Silicic Acid; D013295:Streptococcus mutans / Q000187:drug effects; D014100:Toothpastes; D014260:Triclosan
D000891:Anti-Infective Agents, Local; D045424:Complex Mixtures; D003802:Dentifrices; D018836:Inflammation Mediators; D014100:Toothpastes; C546060:hydrated silica gel-based toothpaste; D012824:Silicic Acid; D014260:Triclosan; D005459:Fluorides